Company: SWKH
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050155
Chunk: 42

Company: SWK Holdings Corp
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 42
---
 revenue60 — — 60 Benefit from credit losses(931)— — (931)Loss on impairment of intangible assets— 209 — 209 Interest expense240 13 926 1,179 Pharmaceutical manufacturing, research and development expense— 147 — 147 Loss on disposal of inventory— 314 — 314 Depreciation and amortization expense— — 2 2 General and administrative expense110 258 2,918 3,286 Other income expense, net2,419 1,601 — 4,020 Income tax expense— — 1,916 1,916 Net income (loss)13,882 660 (5,762)8,780 Three Months Ended September 30, 2024Finance ReceivablesPharmaceutical Development and OtherHolding Company and OtherConsolidatedRevenue$9,498 $628 $— $10,126 Other revenue289 3 — 292 Provision for credit losses1,385 — — 1,385 Interest expense230 2 907 1,139 Pharmaceutical manufacturing, research and development expense— 585 — 585 Depreciation and amortization expense— 214 20 234 General and administrative expense85 722 2,186 2,993 Other income (expense), net292 — — 292 Income tax expense— — 906 906 Net income (loss)8,379 (892)(4,019)3,468 

26

Nine Months Ended September 30, 2025Finance ReceivablesPharmaceutical Development and OtherHolding Company and OtherConsolidatedRevenue$30,077 $2,153 $— $32,230 Other revenue420 116 — 536 Benefit from credit losses(1,635)— — (1,635)Loss on impairment of intangible assets— 209 — 209 Interest expense713 18 2,733 3,464 Pharmaceutical manufacturing, research and development— 1,550 — 1,550 Loss on disposal of inventory— 314 — 314 Depreciation and amortization expense— — 40 40 General and administrative expense236 1,553 7,617 9